With Acurian’s Help, a Crucial Crohn’s Disease Study Completes Enrollment 60% Faster

Gastroenterology

Crohn's Disease

This mid-sized biopharmaceutical company’s growth strategy relies on the development of novel immunotherapy agents. One of its biologics carried the potential to treat a range of autoimmune diseases, including Crohn’s disease or CD. The sponsor believed this agent could fill a substantial, unmet need for CD patients: more effective maintenance therapies that are also safe for long-term use.

Read More »